OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Substance Abuse Treatment is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine	93
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19	78
Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic	75
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder	69
A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose	66
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19	63
Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study	56
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study	54
Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings	54
Implementation of emergency department–initiated buprenorphine for opioid use disorder in a rural southern state	51
A systematic review of stigma interventions for providers who treat patients with substance use disorders	49
Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19	43
Online digital recovery support services: An overview of the science and their potential to help individuals with substance use disorder during COVID-19 and beyond	42
Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use	42
Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19	41
Telehealth sustains patient engagement in OUD treatment during COVID-19	40
COVID-19-related treatment service disruptions among people with single- and polysubstance use concerns	39
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island	39
Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms	38
The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network	36
Impacts of COVID-19 on residential treatment programs for substance use disorder	36
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?	36
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study	34
The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19	34
Appointment wait-times and arrival for patients at a low-barrier access addiction clinic	34

Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?	33
Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic	32
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems	32
“Now hospital leaders are paying attention”: A qualitative study of internal and external factors influencing addiction consult services	32
Motivational interviewing and culture for urban Native American youth (MICUNAY): A randomized controlled trial	31
COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings	31